Potential Sale of Thorne HealthTech
A Lowcountry nutritional supplements business, previously known as Thorne HealthTech, is currently being considered for sale by the investment firm that acquired it three years ago.
Possible Buyers
- Unilever: This British multinational, recognized for brands like Dove and Vaseline, is reportedly interested and is exploring a valuation of around $4 billion for Thorne.
- Haleon: Another possible bidder, this lesser-known British company produces Advil and Centrum vitamins. Haleon has refrained from commenting on market rumors.
Business Background
- Thorne was acquired by L Catterton for $680 million in 2023 and relocated most operations to Summerville, South Carolina, in 2018. The move involved a $35 million investment commitment and led to the creation of at least 350 jobs.
Growth During the Pandemic
During the COVID-19 pandemic, Thorne expanded its warehouse space in the Omni Industrial Campus to accommodate increasing demand, resulting in a workforce of over 800 employees and a global customer base of seven million.
Market Potential
- Thorne has aspirations to become a billion-dollar brand, with projected sales reaching $650 million by 2026—up from $229 million in 2022—driven primarily by health-conscious consumers.
Conclusion
The ongoing speculation regarding the sale represents significant interest in the nutritional supplement market, which is expected to continue growing in the coming years.
For more information, visit Thorne’s official site.
